Introduction: Urosepsis is life threatening, unless treated immediately. Empirical treatment with appropriate antibiotics lowers the risk of a poor outcome. However, with increasing resistance among common uropathogens, there is a need for continuous review of the existing protocol to determine whether there is a correlation between empirical antibiotic therapy and in-vitro susceptibility pattern of the pathogens causing urosepsis. Methodology: A prospective study was carried out on 66 confirmed cases of urosepsis from January 2017 to December 2018 after obtaining ethical clearance. Demographic details, risk factors, length of hospital stay, bacteriological profile, empirical antibiotic given, and change in antibiotic following susceptibility report and outcome was recorded. Results: Among the 66 urosepsis cases 63 of them were started on empiric antibiotic. The correlation between the empirical antibiotic given and the in-vitro antimicrobial susceptibility was found to be significant with a p value < 0.0001. Among the 63 for whom empiric antibiotics was started further escalation of antibiotic was done in 46 patients. The remaining 20% of cases were changed over to a different antibiotic, in line with susceptibility report. The mortality rate was (15.1%) with a confidence interval of (CI = 15 ± 3.5). The association between the risk factors for urosepsis and their effect on mortality rate was analyzed. Diabetes mellitus and chronic kidney disease were identified as important independent risk factors and had direct influence on the mortality rate with significant p value of 0.0281 and 0.0015 respectively. Conclusions: A significant correlation was identified between the empirical antibiotic given and in-vitro antibiotic susceptibility pattern.
<p class="abstract"><strong>Background:</strong> The objectives were to study the bacterial pathogens of ear, nose and throat (ENT), to determine the culture and sensitivity pattern of ENT infections in coastal Karnataka.</p><p class="abstract"><strong>Methods:</strong> A retrospective culture and sensitivity profiling study of 109 samples from September 2018 to September 2019 was done in Department of ENT in KVG Medical College and Hospital. </p><p class="abstract"><strong>Results:</strong> Among the pure growth, <em>Pseudomonas aeruginosa</em> was isolated in majority of samples (27.77%) followed by <em>Staphylococcus aureus</em> (22.9%). <em>Klebsiella </em>sp<em>.,</em> <em>Acinetobacter </em>sp., <em>Citrobacter</em>, <em>Non enterococcus</em>, <em>Escherichia coli</em>, <em>Proteus </em>sp. and <em>Streptococcus pneumoniae</em> were responsible for remaining samples. Among <em>S. aureus</em> majority was MRSA accounting for 18.51%. <em>P. aeruginosa</em> was most sensitive to amikacin, ceftazidime, meropenem and piperacillin- tazobactam and least sensitive to cotrimoxazole and colistin and most resistant to sparfloxacin, cefaperazone-sulbactam, ceftriaxone-tazobactam and clindamycin. MRSA was most sensitive to gentamicin, amikacin and clindamycin and most resistant to cephalexin, ampicillin and ciprofloxacin. <em>Klebsiella </em>sp<em>.</em> was most sensitive to amikacin and cotrimoxazole and most resistant to sparfloxacin and ceftriaxone<em>. E. coli</em> was most sensitive to gentamicin and cotrimoxazole and most resistant to sparfloxacin.</p><p><strong>Conclusions:</strong> <em>P. aeruginosa, S. aureus</em> and <em>Klebsiella </em>sp<em>. </em>represent majority of culture samples. With ever changing culture & sensitivity pattern and rising antibiotic resistance, a simple step of sending pus samples for the same will help in personalizing the treatment, thereby reducing the disease burden. </p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.